NEWS
LATEST
FULL LIST
-
Tissue Regenix recent results and what to watch
Tissue Regenix Group PLC (LSE: TRX) is rapidly becoming a real-world case study in how an innovative biofabrication technology can evolve into a sustainable business. After more than a decade of refining its patented dCELL® decellularisation process which removes donor cells and DNA to leave an immunologically “quiet” scaffold the company now supplies orthopaedic, wound-care,…
-
Tides Medical and UToledo Health Pioneer 3D Bioprinted Grafts for Chronic Wound Care
UToledo Health has become one of the first healthcare systems in the U.S. to implement 3D bioprinted grafts derived from a patient’s own fat cells in the treatment of chronic wounds. The approach marks a major advancement in regenerative medicine, offering a personalized solution for patients with wounds that have resisted conventional healing methods. A…
-
Vertex’s Zimislecel Shows Early Promise for Insulin Independence
Phase 1/2 Trial Demonstrates Glycemic ControlIn an open-label Phase 1/2 segment of its ongoing pivotal study, Vertex Pharmaceuticals reported that all 12 participants achieved blood glucose levels within the American Diabetes Association’s recommended range at least one year after receiving a single infusion of its stem cell–derived islet cell therapy, zimislecel. Ten of those 12…
-
3DBioFibR Secures $3M to Scale High-Performance Biopolymer Fiber Manufacturing
Funding supports ISO 13485-compliant production and expansion into regulated markets Strategic Financing Round Advances Commercial Growth Nova Scotia-based biomaterials company 3DBioFibR has raised CAD $3 million in an equity financing round to scale its dry-spinning platform for manufacturing high-performance biopolymer fibers. The round was led by AoA (Angel of Angels) Ventures, with participation from Build…
-
Biofabricated Organ Support: miroliverELAP’s First Human Treatment for Acute Liver Failure
Overview On June 24, 2025, United Therapeutics Corporation (Nasdaq: UTHR) and Intermountain Health treated the first patient in a Phase 1 clinical trial of miroliverELAP®, an external liver support system that leverages a bioengineered porcine scaffold repopulated with human cells. This landmark event marks the world’s first human use of a bioengineered organ alternative designed…
-
Vivodyne Raises $40M to Scale AI and Robotics-Driven Human Tissue Platform for Drug Discovery
Funding Round and Expansion Vivodyne has secured $40 million in Series A funding to advance its human tissue-based drug development platform. The investment will support the expansion of its robotics and AI-powered preclinical testing infrastructure, including a new 23,000-square-foot automated lab at Genesis Marina in South San Francisco. The facility is designed to meet growing…
-
Vital3D Targets Pet Care Market as Strategic Entry Point to Bioprinted Human Organs
Commercial Focus Begins with Veterinary Wound Care Lithuanian startup Vital3D is positioning itself at the forefront of bioprinted organ development, with a projected timeline of 10 to 15 years for human applications. As a first step toward that goal, the company is entering the market with VitalHeal, a 3D-bioprinted wound patch for pets — beginning…
-
OrganOx Secures $160M in Private Financing to Accelerate Organ Perfusion Technology Expansion
Oxford, UK – May 8, 2025 — OrganOx Ltd. has completed the second closing of a $160 million private financing round, bringing in new strategic investors Intuitive Ventures and Terumo Ventures. The investment will support the company’s continued expansion of its metra® perfusion technology, which aims to improve transplant outcomes and organ availability globally. Technology…
-
Collagen-Based 3D Bioprinting Offers Fully Perfusable Gel Based Organ-On-Chips
A team of bioengineers at Carnegie Mellon University has unveiled a new tissue engineering platform. The study, published in Science Advances, introduces CHIPS (Collagen-based High-resolution Internally Perfusable Scaffolds), a new class of biological, perfusable 3D-printed tissue constructs, and VAPOR, a customizable perfusion bioreactor designed to support them. What’s the Technology? The platform uses an improved…
-
Quris Technologies Demonstrates Liver-Driven Brain Toxicity in New Multi-Organ Model
A recent study by Quris Technologies highlights how drug metabolism in the liver can significantly alter a compound’s neurotoxicity, providing new insights into limitations of traditional drug testing methods. Published in Biomedicine & Pharmacotherapy, the findings suggest a greater role for multi-organ, human-relevant testing platforms in preclinical development. Using a proprietary platform called BioAI, Quris…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 